1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Adverse Effect: new trials by email Literature Review of Adverse Effect trials Research Report on Adverse Effect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
Uterine Cervical Neoplasms (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Cervical Diseases (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Paclitaxel (1)
Lei Li (1)
China (1)
Lei Li, M.D. (1)